Aligos Therapeutics, Inc. (ALGS) is a Biotechnology company in the Healthcare sector, currently trading at $8.55. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is ALGS = $20 (+133.9% upside).
Valuation: ALGS trades at a trailing Price-to-Earnings (P/E) of -3.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.13.
Financials: revenue is $2M, -35.8%/yr average growth. Net income is $24M (loss), growing at +13.5%/yr. Net profit margin is -1106.7% (negative). Gross margin is 57.5% (-16.1 pp trend).
Balance sheet: total debt is $5M against $54M equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 3.9 (strong liquidity). Debt-to-assets is 5.9%. Total assets: $89M.
Analyst outlook: 3 / 5 analysts rate ALGS as buy (60%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 35/100 (Fail), Future 73/100 (Pass), Income 10/100 (Fail).
